Obesity Management Market to reach US$ 1,078.9 Mn by 2027

Posted by Vikas Bahurupi on July 13th, 2018

The global obesity management market is expected to increase at a y-o-y growth rate of over 4.9% and reach US$ 1,078.9 Mn in revenues in 2027. North America and APEJ has collectively accounted for nearly 47.1% revenue share of the obesity management market in 2016. The increasing population of diabetes people worldwide and increasing prevalence of lifestyle diseases are some of the major factors favouring the growth of the global obesity management market. Increasing awareness about the health concerns due to obesity and overweight resulting in the increasing demand for the anti-obesity drugs and bariatric procedures which fuel the growth of the global obesity management market. Asia Pacific and MEA regions are the highest population regions. The increase in health care infrastructure and increasing medical tourism in these regions is expected to play an important role in driving growth of global obesity management market.

 Report For Report Sample with Table of Contents@  https://www.researchreportinsights.com/report/sample/110114820/Obesity-Management-Market

The rise in investments to develop novel anti-obesity drugs and the strategic collaborations among companies, research institutes and universities for novel drug development and patent transfer are also anticipated to fuel the growth of this market over the forecast period. The increasing focus on body toning and grooming therapy as greater emphasis on the aesthetic appearance is also one of the important factor fuelling the revenue growth of the global obesity management market. 

Global Obesity Management Market Revenues to Grow by Over 4.9% in 2017 to Reach US$ 1,078.9 Mn in Revenues in 2027: RRI Report 

On the basis of drugs type, the obesity management market is segmented into bupropion and naltrexone, orlistat, lorcaserin, phentermine and topiramate, and Liraglutide. The liraglutide drug is expected to contribute the highest market share of 34.7% in 2027 and expected to register a significant CAGR of 6.2% during the forecast period 2027. Orlistat drug will have the major market share, followed by liraglutide. The availability of orlistat throughout the world is expected to boost the market over the forecast period. Gastric sleeve surgery will remain the largest segment by the surgery, accounted for over 39.6% revenue share of the market in 2016. The Increasing preference to the gastric sleeve surgery due to shorter hospital stays, faster recovery with the smaller scars and less pain as compared to other surgical procedures. 

Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114820/Obesity-Management-Market